NCT06901817View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

Intraventricular Pemetrexed

Intraventricular injection of 30 mg pemetrexed via Ommaya reservoir, once every 4 weeks until disease progression.

DRUG

Intraventricular Nivolumab

Intraventricular injection of 40 mg nivolumab via Ommaya reservoir, once every 4 weeks until disease progression.

DRUG

Intraventricular Dexamethasone

Intraventricular injection of 5mg/2ml pemetrexed via Ommaya reservoir before injection of pemetrexed and nivolumab.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Cancer Hospital, China

OTHER